Moderna Cancer Vaccine Data Leak Sends Shares Tumbling Despite Trial Success

Moderna's experimental cancer vaccine had become a major source of investor optimism before the data arrived. According to Forbes, enthusiasm for the personalized treatment helped fuel a large rally in Moderna shares during 2026.

Developed with Merck, the treatment uses mRNA and is personalized to the patient's tumor, according to ANSA. It is a therapeutic vaccine for people with cancer, rather than a conventional preventive vaccine against an infectious disease, as News18 explained.

The companies were expected to present Phase 3 results at a medical conference over the weekend, MarketWatch reported on October 22. Partial data reached investors first.

On October 22, Moderna shares plunged after partial trial data leaked. Forbes reported a 25 percent drop. CNBC reported that full results released later that Thursday appeared positive against Wall Street's expectations before the release, despite the selloff.

The detailed results confirmed that the trial met key endpoints, according to STAT News. The vaccine reduced the risk of melanoma recurrence by 42 percent compared with standard treatment, the outlet reported. The Associated Press also reported a 42 percent reduction in the risk of melanoma returning.

There is a numerical conflict in the coverage. The Financial Times reported a 58 percent reduction in recurrence or death, while Ars Technica Tech reported 42 percent for recurrence or death. The supplied reports do not explain that discrepancy.

On October 23, the divide between medical and market reactions became clearer. Six melanoma specialists told CNBC that the findings represented a clinically meaningful result for patients who had undergone surgery. Bloomberg likewise described doctors celebrating results that investors had sold off.

By October 25, discussion had turned toward extending the treatment's impact, STAT News reported after the pivotal trial presentation in Madrid. On October 26, MarketWatch described investors' expectations for the Phase 3 results as "incredibly high," while Bloomberg reported that Moderna CEO Stephane Bancel believed the vaccine could work across a variety of tumors.

The stock reaction and the clinical findings tell different parts of this story. Investors were judging a highly anticipated experimental treatment against demanding expectations. Specialists interviewed by CNBC judged the results meaningful for melanoma patients after surgery.

The vaccine remains experimental. New Scientist reported expectations for approval next year in the US, Europe and the UK, but that is a forecast, not an approval decision. The supplied coverage does not establish a confirmed availability date.

A central question is how long protection lasts. MarketWatch identified keeping cancer from returning over the long term as the treatment's real test. That matters beyond the initial percentage reduction and the immediate share-price response.

Another question is whether success in melanoma can translate to other cancers. Bancel expressed confidence in that possibility, according to Bloomberg, but the supplied coverage does not establish effectiveness in other tumor types.